Streetbeat News

Analyst Ratings

ACAD

JMP Securities analyst Jason Butler has maintained an Outperform rating on ACADIA Pharmaceuticals (ACAD) but has lowered the price target from $44 to $39.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:48 am

MSTR

TD Cowen analyst Lance Vitanza maintains an Outperform rating on MicroStrategy (NASDAQ:MSTR) and raises the price target from $1220 to $1560.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:46 am

ACAD

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a maintained price target of $33.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:45 am

TSLA

Canaccord Genuity analyst George Gianarikas views Tesla Inc (TSLA) as a solid buy, setting a price target of over $230. He attributes the current stock slump to poor earnings revisions but is optimistic about Tesla's growth in vehicle prices, next-gen vehicles, FSD adoption, and energy storage. Despite aggressive price cuts to boost sales, Tesla's strategy pressures rivals and maintains competitiveness, especially in the US, Europe, and China.

Portfolio Pulse from Anan Ashraf

March 12, 2024 | 10:45 am

AMLX

HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Amylyx Pharma (NASDAQ:AMLX) but has significantly lowered the price target from $42 to $8. This adjustment reflects a substantial change in the valuation outlook for Amylyx Pharma.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:43 am

EXK

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Endeavour Silver (NYSE:EXK) but lowers the price target from $6 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:41 am

UEC

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Uranium Energy (AMEX:UEC) and raises the price target from $9.75 to $10.25.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:40 am

OLMA

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Olema Pharmaceuticals (NASDAQ:OLMA) but lowers the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:40 am

DLTR

JP Morgan analyst Matthew Boss maintains an Overweight rating on Dollar Tree (NASDAQ:DLTR) and raises the price target from $157 to $165.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:38 am

SLRN

HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:28 am